Product Information
ATORVALIQ 20 MG/5 ML SUSP is a brand product labeled by CMP Pharma, Inc., priced at $1.2348 per ML under NDC 46287003001. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Feb 1, 2023.
Strength
20 mg/5mL
Manufacturer
CMP Pharma, Inc.NDC
46287003001
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
10/1/2026
Active Ingredients
ATORVASTATIN CALCIUM TRIHYDRATEApproval Type
New Drug (NDA)
FDA Application
NDA213260FDA Approved
2/1/2023
On Market Since
3/1/2023
Pharmacological Classes
Price Statistics
The NADAC for ATORVALIQ 20 MG/5 ML SUSP has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 10.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2348 per ML |
|---|---|
| All-time high | $1.2348 (Sep 30, 2026) |
| All-time low | $1.1103 (Apr 23, 2025) |
| 52-week high | $1.2348 |
| 52-week low | $1.1872 |
| Median price | $1.1505 |
| Average price | $1.1563 |
| Largest weekly change | +4.0% (Sep 30, 2026) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ATORVALIQ market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Weekly brief
Featured in the latest weekly brief
This NDC appears in the current executive summary of the most important weekly NADAC moves.
Manufacturer
CMP Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ATORVALIQ market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
HMG-CoA Reductase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ATORVALIQ 20 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for ATORVALIQ 20 MG/5 ML SUSP, manufactured by CMP Pharma, Inc., is $1.2348 per ML (NDC 46287003001), effective Sep 30, 2026.
How has the price of ATORVALIQ 20 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for ATORVALIQ 20 MG/5 ML SUSP has risen 10.1%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for ATORVALIQ 20 MG/5 ML SUSP?
Since Apr 17, 2024, the NADAC for ATORVALIQ 20 MG/5 ML SUSP has ranged from a low of $1.1103 (Apr 23, 2025) to a high of $1.2348 (Sep 30, 2026), with a median of $1.1505 per ML.
Are there cheaper alternatives to ATORVALIQ 20 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of ATORVALIQ 20 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ATORVALIQ 20 MG/5 ML SUSP?
ATORVALIQ 20 MG/5 ML SUSP (NDC 46287003001) is labeled by CMP Pharma, Inc., and CMS classifies it as a brand product.